Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models
(Thomson Reuters ONE) -
Addex Therapeutics /
Addex Announces the Publication of Positive Data on the Efficacy of mGluR4
Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Seminal Research Provides Greater Insight into the Role of Selective mGluR4
Modulation on Motor Symptoms in Parkinson's disease
Geneva, Switzerland, 16 July 2012 - Addex Therapeutics (SIX:ADXN), a leading
company pioneering allosteric modulation-based oral small molecule drug
discovery and development, announced today the publication of positive pre-
clinical efficacy data on its novel, highly selective oral small molecule
positive allosteric modulator (PAM) of metabotropic glutamate receptor 4
(mGluR4), and its role in Parkinson's disease. The results were published in
the Journal of Pharmacology and Experimental Therapeutics (JPET) on 11 July
2012 as DOI:10.1124/jpet.112.196063. The researchers report the discovery of
ADX88178, a novel, potent, brain penetrant and selective mGluR4 PAM, with drug-
like properties, to explore the therapeutic potential of mGluR4 modulation in
disease models. The research was conducted in collaboration with Merck & Co.
"There continues to be a significant need for new approaches to treat
Parkinson's disease. Research shows that increasing mGluR4 activity could
normalize the aberrant synaptic transmission resulting from dopamine depletion
and restore normal activity in the brain circuits that control movement,"
explained Dr. Graham Dixon, Chief Scientific Officer at Addex. "The allosteric
modulation approach enables modulation of mGluR4 with exquisite selectivity and
our research provides compelling evidence and validation for mGluR4 activation
for the treatment of Parkinson's disease and a host of other indications through
a non-dopaminergic approach."
Study Details
The publication entitled, "A potent and selective mGluR4 positive allosteric
modulator improves movement in rodent models of Parkinson's disease" reported
that ADX88178, an mGluR4 selective, potent, orally available and brain penetrant
small molecule, has the potential to ameliorate the Parkinsonian symptoms as
shown in two rodent models of dopamine depletion. ADX88178 was found to enhance
glutamate-mediated activation of human and rat mGluR4 with EC(50) values of 3.5
and 9.1 nM respectively. ADX88178 is a potent allosteric modulator of mGluR4
that shows excellent selectivity against other metabotropic glutamate receptors.
Oral administration of ADX88178 in rats was associated with high bioavailability
and was able to readily penetrate into the brain. ADX88178 was shown to reverse
haloperidol-induced catalepsy in rats at 3 and 10 mg/kg. More importantly, the
combination of ADX88178 (3, 10 and 30 mg/kg, p.o.) with a low dose of L-DOPA
enabled a robust, dose-dependent reversal of the forelimb akinesia deficit
induced to a bilateral 6-OHDA lesion of the striatum in rats. Similar
synergistic effect was also demonstrated with Dopamine D2 agonist, Quinpirole.
In addition, co-administration of ADX88178 (10 mg/kg, p.o.) did not worsen
dyskinesia induced by L-DOPA in rats subjected to a unilateral 6-OHDA lesion of
the medial forebrain bundle. This is consistent with an L-DOPA sparing action
that may prove to be therapeutically useful for the management of motor symptoms
of PD. ADX88178 is an invaluable proof of concept candidate in that it appears
to be the most potent of the mGluR4 PAM molecules reported to date, and also has
a greater window of selectivity against mGluRs, as well as other non-GPCR
targets.
"This is another example of the power of Addex' platform to identify and develop
oral, highly selective, brain penetrant compounds with adequate drug-like
properties where others faced "flat" structure-activity relationship (SAR) and a
poor developability profile" commented Sylvain Celanire, Head of the mGluR4
program at Addex. "We are excited by these preclinical results and are looking
forward to rapidly advancing our lead molecule into the clinic"
About mGluR4
The metabotropic glutamate receptor 4 (mGluR4) belongs to the Group III mGluRs
(Class C G-Protein Coupled Receptor) and is negatively coupled to adenylate
cyclase via activation of the Gαi/o protein. It is expressed primarily on
presynaptic terminals, functioning as an autoreceptor or heteroceptor and its
activation leads to decreases in transmitter release from presynaptic terminals.
MGluR4 is currently receiving much attention based primarily upon its unique
distribution in key brain region involved in many CNS disorders. In particular,
mGluR4 is abundant in striato-pallidal synapses within the basal ganglia
circuitry a key area for motor control. MGluR4 PAM is therefore emerging as a
promising target for the treatment of motor (and non motor) symptoms as well as
a disease-modifying agent in Parkinson's disease through a non-dopaminergic
approach. In addition to the search for novel drugs that relieve motor symptoms
of Parkinsonism, attenuating the ongoing degeneration of nigrostriatal neurons
is also of increasing interest. Orthosteric mGluR4 agonist L-AP4 has
demonstrated neuroprotective effects in a 6-OHDA rodent model of PD and first
discovered allosteric potentiator (-)-PHCCC reduced nigrostriatal degeneration
in mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP). Those
studies provide preclinical evidence suggesting that mGluR4 activators
constitute a strong approach not only for symptomatic treatments of PD, but also
potentially as disease modifiers.
Emerging data for other therapeutic indications such as anxiety, multiple
sclerosis, neuropathic and inflammatory pain, schizophrenia and diabetes make
mGluR4 a highly promising target for both CNS and non CNS diseases. In
particular, anxiety disorders are among the most prevalent psychiatric disorders
in the world, and are co-morbid with Parkinson's disease. Addex has reported in
2010 that ADX88178 demonstrated oral efficacy in two preclinical rodent models
of anxiety: the marble burying test in mice and EPM in mice and rats. The
mGluR4-mediated specific effect has been also confirmed in knock-out mice.
Therefore, mGluR4 activators may represent a new generation of anxiolytic
therapeutics. More recently, mGluR4 PAM PHCCC demonstrated efficacy in a
neuroinflammation model, the remitting-relapsing EAE model, by promoting
regulatory T-cell (Treg) formation and reverse pro-inflammatory T-cell release.
Therefore, positive modulation of mGluR4 could potentially stop the destruction
of myelin in MS in a robust and durable manner.
Addex Therapeutics (www.addextherapeutics.com) discovers and develops an
emerging class of small molecule drugs, called allosteric modulators, which have
the potential to be more specific and confer significant therapeutic advantages
over conventional "orthosteric" small molecule or biological drugs. The Company
uses its proprietary discovery platform to address receptors and other proteins
that are recognized as attractive targets for modulation of important diseases
with unmet medical needs. The Company's two lead products are being investigated
in Phase 2 clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in patients
suffering from major depressive disorder. Addex also is advancing several
preclinical programs including: GABA-BR PAM for overactive bladder, pain and
other disorders; mGluR4 PAM for Parkinson's, MS, anxiety and other diseases;
GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's disease
and depression. In addition, Addex has discovery programs to identify allosteric
modulators of: receptor tyrosine kinase (RTK) superfamily, including TrkB PAM
for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and
Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM for
inflammation (e.g. rheumatoid arthritis) and other diseases.
Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR(at)addextherapeutics.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the
potential approval of its products by regulatory authorities, or regarding
potential future revenues from such products. Such forward-looking statements
reflect the current views of Addex Therapeutics regarding future events, future
economic performance or prospects, and, by their very nature, involve inherent
risks and uncertainties, both general and specific, whether known or unknown,
and/or any other factor that may materially differ from the plans, objectives,
expectations, estimates and intentions expressed or implied in such forward-
looking statements. Such may in particular cause actual results with allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other
therapeutic targets to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR,
GLP1R, TNFR1, TrkB or other therapeutics targets will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or
other therapeutic targets will achieve any particular levels of revenue (if any)
in the future. In particular, management's expectations regarding allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or other
therapeutic targets could be affected by, among other things, unexpected actions
by our partners, unexpected regulatory actions or delays or government
regulation generally; unexpected clinical trial results, including unexpected
new clinical data and unexpected additional analysis of existing clinical data;
competition in general; government, industry and general public pricing
pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Therapeutics is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise, except as may be required by applicable
laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Therapeutics via Thomson Reuters ONE
[HUG#1626858]
Unternehmensinformation / Kurzprofil:
Datum: 16.07.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 165258
Anzahl Zeichen: 13254
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
